Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — Corporate Update (August 2026)
21 slides from Silence Therapeutics's corporate update, Aug 10, 2026
Slide 1: SANRECO Phase 2 Topline Results in Polycythemia Vera
August 10, 2026 SANRECO Phase 2 Topline Results in Polycythemia Vera Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation
Slide 3: Introduction
Introduction Iain Ross, Chairman and Interim Principal Executive Officer
Slide 4: Silence – siRNA Platform Company with Compelling Clinical Data Across Multiple Programs
Silence – siRNA Platform Company with Compelling Clinical Data Across Multiple Programs GOLD PLATFORM Proven GalNAc siRNA technology with broad utility Potent, durable and highly specific gene silencing Infrequent dosing enabled by durable pharmacology Strong and growing IP portfolio CLINICAL RESULT
Slide 5: PV: Large Unmet Need and Proven Market Value Create Significant Upside
PV: Large Unmet Need and Proven Market Value Create Significant Upside for a Best-in-Class Therapy Large Underserved Population 2-5 Many PV patients remain phlebotomy-dependent Persistent burden reflects inadequate control Broad addressable population needs better therapy Current Options are Limited
Slide 6: SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients
SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients Efficacy Endpoints Safety Endpoints Infrequent Dosing
Slide 7: SANRECO Phase 2 Topline Results
SANRECO Phase 2 Topline Results Steven Romano, MD, Chief R&D Officer
Slide 8: Divesiran Clinical Development Program
Preclinical Phase I Phase II Key Milestones Divesiran (TMPRSS6) Divesiran Clinical Development Program Polycythemia Vera PV is a rare myeloproliferative neoplasm characterized by excessive production of red blood cells Elevated hematocrit (Hct) >45% Primary treatment goal is to maintain Hct <45% HEM
Slide 9: Phase 2 SANRECO Study is a Global Trial
Phase 2 SANRECO Study is a Global Trial: 9 Countries / 4 Continents
Slide 10: Phase 2 SANRECO Study: Clinical Study Design
Phase 2 SANRECO Study: Clinical Study Design
Slide 11: SANRECO Phase 2 Study Overview
SANRECO Phase 2 Study Overview Design 36-week, placebo-controlled, double-blind period followed by a 3-year, double-blind and open-label extension period evaluating divesiran in 48 phlebotomy-dependent PV patients Key Inclusion Criteria PV diagnosis At least 3 phlebotomies in the last 6 months or 5
Slide 12: SANRECO: Primary Efficacy Endpoint - Response Rate
SANRECO: Primary Efficacy Endpoint - Response Rate The primary endpoint was met: Significantly higher proportion of clinical responders among the divesiran treated PV patients (88%) compared to those who received placebo (19%) during weeks 18-36; p<0.0001 Placebo adjusted response rate = 69% Note: R
Slide 13: SANRECO: Primary Efficacy Endpoint by Dose Groups
SANRECO: Primary Efficacy Endpoint by Dose Groups Note: Response is defined as HCT remaining below 45% and no phlebotomies received during weeks 18-36 18.8% 81.3% 93.8%
Slide 14: SANRECO: Response Rate Sensitivity Analysis (n=40)
SANRECO: Response Rate Sensitivity Analysis (n=40)* Significantly higher proportion of clinical responders among the divesiran treated PV patients (89%) compared to those who received placebo (8%) during weeks 18-36; p<0.0001 Placebo adjusted response rate = 81% Note: Response is defined as HCT rema
Slide 15: SANRECO: Key Secondary Endpoint - Phlebotomy Rate
SANRECO: Key Secondary Endpoint - Phlebotomy Rate Mean number of phlebotomies in the divesiran arm was 0.2 compared to 2.1 phlebotomies in the placebo arm during weeks 0-36 (p<0.0001) 12.5% 90.6%
Slide 16: SANRECO: Other Secondary Endpoints
SANRECO: Other Secondary Endpoints Divesiran groups also showed improvements in: Hematocrit control Iron markers, including ferritin Patient reported outcomes using MPN-SAF Total Symptom Score (MPN-SAF TSS)
Slide 17: Summary of Adverse Events (Weeks 0-36)
Summary of Adverse Events (Weeks 0-36) Divesiran was generally well tolerated Safety profile was in line with previous divesiran trials; no new safety findings Injection site reactions were infrequent and self-limiting There were two investigator reported grade 1 anemia adverse event cases
Slide 18: Next Steps
Next Steps Phase 2 SANRECO full results Submitted abstract to ASH Congress (Dec 12-15, New Orleans) End of Phase 2 meeting by year end Initiate Phase 3 study in 1H 2027
Slide 19: SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients
SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients Phase 2 profile supports potential best-in-class positioning in phlebotomy-dependent PV
Slide 20: Q&A
Q&A
Slide 21: Thank You
} SILENCE THERAPEUTICS > THANK YOU!
Silence Therapeutics — Corporate Update (August 2026) on 6ix